

Attachment 2: 2015 IMAT Evaluation Web-based Survey - Screenshots

1%

SURVEY OF TECHNOLOGY DEVELOPMENT GRANTS


OMB No.: 0925-XXXX Expiration Date: xx/xx/20xx Collection of this information is authorized by The Public Health Service Act, Section 410 (42 USC 285). Rights of participants are protected by The Privacy Act of 1974. Participation is voluntary, and there are no penalties for not participating or withdrawing from the study at any time. The information collected in this study will be kept private to the extent provided by law. Names and other identifiers will not appear in any report of the study. Information provided will be combined for all participants and reported as summaries. You are being contacted by email to complete this survey as part of a full-scale evaluation of the Innovative Molecular Analysis Technologies (IMAT) Program. Public reporting burden for this collection of information is estimated to average 30 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: NIH, Project Clearance Branch, 6705 Rockledge Drive, MSC 7974, Bethesda, MD 20892-7974, ATTN: PRA (0925-XXXX). Do not return the completed form to this address.

You have been selected as a member of the research community who has previously received a grant award from the National Institutes of Health (NIH) for support of technology development research. This survey is part of a comprehensive evaluation of the Innovative Molecular Analysis Technologies (IMAT) program of the National Cancer Institute (NCI). Your experience and views regarding NIH support for the development of highly innovative technologies to advance biomedical research and clinical care capabilities will directly inform this evaluation and as such, NCI appreciates your willingness to participate.

Thank you for your time and support. Click the Continue button below to begin the survey.

Continue

POWERED BY SURVEY ANALYTICS



SURVEY OF TECHNOLOGY DEVELOPMENT GRANTS

Grant Number

Institution

Please confirm that the institution on the grant is correctly listed above. If not, please correct it below.

- Yes, it is correct
- No, it should be recorded as:

Title of Grant

Your role on the grant

Please confirm that your role on the grant is correctly listed above. If not, please correct it below.

- Yes, it is correct
- No, it was:

Continue

Please select the most appropriate categorization of your technology/methodology developed under this grant (Select all that apply).

- Small Molecules:** Tools or methods for the development or reformulation of drugs as chemical substances used in the treatment, cure, prevention, or diagnosis (in vivo, imaging agents, etc.) of disease or used to otherwise enhance physical or mental well-being; includes so-called "naturopathic" or naturally-derived substances in alternative care regimes.
- Biologics:** Tools or methods that facilitate the development of medicinal products created by biologic processes, such as a vaccine, blood or blood component, allergenic, somatic cell, gene therapy, tissue, recombinant therapeutic protein, or living cells.
- Companion Product:** A diagnostic, therapeutic, or device that must be used in combination with another diagnostic, therapeutic, or device type (e.g. companion diagnostic for a specific therapy; a small molecule that activates expression from a gene therapy vector; a device and imaging agent that work together). This does not include "drug cocktails."
- Medical Devices:** The development and/or use of instruments or machines, used in the diagnosis of disease or in the cure, mitigation, treatment, or prevention of disease or conditions associated with the deterioration of physiological function (e.g., prostheses); this would also include medical imaging devices and the use of innovative materials to construct new devices.
- Research Tools:** The development of new or improved tools, devices, methods, and sensors to enhance laboratory or field studies on humans, animals, or any model system. This includes tools and methods that broaden the research knowledge base and for biomonitoring.
- Biotechnology:** Tools or methods that facilitate the use of microorganisms, such as bacteria or yeasts, to perform specific industrial or manufacturing processes.
- In Vitro and Ex Vivo Diagnostics:** The use of tools (software, hardware or combinations) to identify or screen for medical conditions and determine whether specified diseases or disease processes are present in living organisms. Includes the use of these tools for non-clinical screenings and to provide insights in the work of clinicians, providers, manufacturers of equipment, and companies involved in therapies associated with disease.
- Healthcare IT:** Approaches and tools derived from information technology that allow for the management of research, educational and medical information. Includes software, media, educational tools, and digital health.

Other

Continue


29%**SURVEY OF TECHNOLOGY DEVELOPMENT GRANTS**

To which disease(s) or research area(s) does your technology apply? (Select all that apply)

- Aging
- Alcohol Abuse and Alcoholism
- Allergy, Autoimmune, and Infectious Diseases
- Arthritis and Musculoskeletal and Skin Diseases
- Behavioral and Social Sciences Research
- Biomedical Imaging and Bioengineering
- Cancer
- Cardiovascular Research (Heart, Lung, and Blood)
- Child Health & Human Development
- Complementary and Alternative Medicine
- Deafness and Other Communication Disorders
- Dental and Craniofacial Research
- Diabetes and Digestive and Kidney Diseases

- Dietary Supplements
- Drug Abuse and Addiction
- Environmental Health Sciences
- Eye Disease and Disorders of Vision
- General Medical Sciences
- Genetics/Genomics
- Global Health
- HIV/AIDS
- Mental Health
- Minority Health and Health Disparities
- Neurological Disorders and Stroke
- Nursing Research
- Translational Research
- Women's Health

Continue

38%

SURVEY OF TECHNOLOGY DEVELOPMENT GRANTS

ABOUT YOUR TECHNOLOGY (Cont.)

Please list any preceding technology(ies) or methodology(ies) for which your own technology or methodology offered superior performance capabilities. Please list no more than 5, separated by a semi-colon.

Did the technology/methodology that you developed under the Grant XXX award have any relation to an earlier technology/methodology used by you or someone else?

- Yes, by me
- Yes, by someone else
- No

Please indicate the number of individuals (by type) who are, or were, on your research team for this grant. Note this includes investigators, post-doctoral researchers, and students.

Engineers

Clinicians

Chemists

Biologists

Molecular Biologists

Biochemists

Biophysicists

Materials scientists

Physicists

Other

How would you best categorize the stage of development your technology/methodology was in prior to grant award?

- Concept only – no reasonable development undertaken
- Non-clinical technology/methodology in prototype development/testing stage
- Non-clinical technology/methodology in full development/testing stage
- Pre-clinical development
- Commercially available

Did your grant objectives (e.g., aims) formally change over the course of grant period?

- Yes
 - No
-

Continue

42%

SURVEY OF TECHNOLOGY DEVELOPMENT GRANTS

The following two questions are related to the original application submission time period.

Did you apply to another NIH award program to support this research idea?

- Yes
- No

Would other NIH programs have been a suitable fit for your NIH application?

- Yes, at least one program may have worked for me
- Yes, several of these programs may have worked for me
- No, this program was the only one that was appropriate for this research idea


46%**SURVEY OF TECHNOLOGY DEVELOPMENT GRANTS****INTERACTIONS**

Prior to grant award, were meetings/discussions with NIH grant representatives (e.g., program officers, grant staff) productive and useful in developing the research/technology for your grant?

- Yes
 - Somewhat
 - No
 - I did not participate in meetings prior to grant award
-

During the grant period, were interactions with NIH program officers and grant staff productive and useful in developing the technology/methodology?

- Yes
 - Somewhat
 - No
 - I had no interactions with NIH staff during the grant period
-

[Continue](#)



53%

SURVEY OF TECHNOLOGY DEVELOPMENT GRANTS

Please elaborate on the utility of these interactions in developing the technology/methodology.

Did your attendance at grant meetings help catalyze new projects with collaborators beyond the key personnel on the grant-supported technology?

- Yes
- No

How would you best categorize the stage of development for your technology/methodology at the conclusion of the grant?

- Concept only – no reasonable development undertaken
- Non-clinical technology/methodology in prototype development/testing stage
- Non-clinical technology/methodology in full development/testing stage
- Pre-clinical development
- Commercially available
- Discontinued

How would you best categorize the stage of development for your technology/methodology today?

- Concept only – no reasonable development undertaken
- Non-clinical technology/methodology in prototype development/testing stage
- Non-clinical technology/methodology in full development/testing stage
- Pre-clinical development
- Commercially available
- Discontinued
- Don't know

Continue

61%

SURVEY OF TECHNOLOGY DEVELOPMENT GRANTS

Did you achieve the primary objectives of your funded grant?


- Yes, all
- Yes, most
- Yes, some
- No

Despite not achieving all of your grant objectives, please briefly describe the importance of the results you were able to achieve.

Has your research led to a marketable technology or a widely accepted methodology?

- Yes
- No
- This research was not intended to lead to a marketable technology or a widely accepted methodology

Continue


66%

SURVEY OF TECHNOLOGY DEVELOPMENT GRANTS

DISSEMINATING INFORMATION ON GRANT OUTCOMES


For the research/technology funded through the \${GrantInfo3} grant, have you...

	Yes	No
Presented at scientific meetings or conferences	<input type="radio"/>	<input type="radio"/>
Presented to clinical audiences	<input type="radio"/>	<input type="radio"/>
Given seminars	<input type="radio"/>	<input type="radio"/>
Wrote papers and publications	<input type="radio"/>	<input type="radio"/>

Are you aware of any additional technologies that have been developed as a result/extension of the technology you developed from the results of your grant?

Yes

No


70%

SURVEY OF TECHNOLOGY DEVELOPMENT GRANTS

Have others involved with your grants, including any of your students, junior investigators, or colleagues, taken the initial research/technology and moved it forward without your involvement?

Yes

No

75%

SURVEY OF TECHNOLOGY DEVELOPMENT GRANTS

Who has taken the initial research/technology and moved it forward without your involvement? Please specify name, department (if applicable), and institution/organization.


Have any new technologies been developed as a result?

- No
- I do not know.
- Yes, please specify:

How would you categorize the status of your research/technology related to:

	Not applicable	Not planned	Planned	Submitted/Initiated	Approved/Completed	Rejected
Clinical trials	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Licenses	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Patents	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
FDA approval	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
International approval	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>


Continue


79%

SURVEY OF TECHNOLOGY DEVELOPMENT GRANTS

Did the research/technology funded by this grant result in the accomplishment or attainment of any of the following?

	Yes	No	N/A
Strategic partnerships	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Spin-off companies	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Public offering	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Merger or acquisition of awardee	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>


81%


SURVEY OF TECHNOLOGY DEVELOPMENT GRANTS

USE OF RESEARCH/TECHNOLOGY

Has the technology/method already been adopted by any segments of a user community (e.g., clinical, research)?

Yes

No



SURVEY OF TECHNOLOGY DEVELOPMENT GRANTS

How much of an impact would you say this $\{GrantInfo3\}$ grant had in the following areas...

	No Impact	Little Impact	Moderate Impact	Great Impact	N/A (Not a goal of this technology)
Advancement of ability to diagnose	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Advancement of ability to treat	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Improve quality of biospecimens used in clinical management	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Improve utility of biospecimens used in research	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Improve standards/methods for conducting cancer research	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Continue


88%**SURVEY OF TECHNOLOGY DEVELOPMENT GRANTS****FUNDING**

Please select the approximate amount of funding obtained for this research/technology prior to your grant award.

- No funding
- Less than \$50,000
- \$50,000 - \$99,999
- \$100,000 - \$499,000
- \$500,000 - \$999,000
- \$1,000,000 - \$4,999,000
- \$5,000,000 or greater

During or after the grant award period, is/was there other funding support you applied for or received related to use or development of this research/technology?

- I received other funding
- I applied for other funding but did not receive it
- I did not apply for other funding support for this research/technology during the grant period

Continue

98%

SURVEY OF TECHNOLOGY DEVELOPMENT GRANTS

What was the primary purpose of the additional funding?

- Further development of the research/technology for measurement or technical capabilities
 - Application of the technology to a novel hypothesis
-

Who was the source of this funding? (Select all that apply)

- NIH
- NSF
- DOD
- NIST
- Private
- Other, please specify:

What is/was the amount of funding obtained for this research/technology during and after the grant period (excluding this NIH grant award)?

- Less than \$50,000
- \$50,000 - \$99,999
- \$100,000 - \$499,000
- \$500,000 - \$999,000
- \$1,000,000 - \$4,999,000
- \$5,000,000 or greater

Did/does the technology you developed on the \${GrantInfo3} grant play a major role in formulating the proposal for this other funding?

- Yes
- No

Please enter any additional comments you may have related to technology development/methodology, application and post-award processes at NIH, interactions with NIH, or funding.

Continue

100%

SURVEY OF TECHNOLOGY DEVELOPMENT GRANTS

Please enter any additional comments you may have related to areas not covered in this survey.

Continue

Thank you for your time and input. If you have any questions, feel free to contact Tony Dickherber, IMAT Project Officer at 301-547-9980 or by email at dickherberaj@mail.nih.gov.

Thank you for completing this survey

online surveys powered by
SURVEY ANALYTICS